BioSpace News Archive

Drug Development

ZZ Biotech Hit with Data Manipulation Allegations Regarding Stroke Trial

Whistleblowers allege that ZZ Biotech co-founder Berislav Zlokovic pressured his scientists to adjust data in favor of the investigational stroke therapy 3K3A-APC, according to a dossier obtained by Science.

November 15, 2023
·
2 min read
·
Tristan Manalac
Business

Pfizer to Cut 500 Jobs at UK Site as Part of $3.5B Cost-Savings Campaign

On the heels of cutting 100 jobs in Ireland, Pfizer is laying off around 500 workers from its Sandwich, Kent facility in the U.K. under its cost-reduction plan to save $3.5 billion through 2024.

November 15, 2023
·
2 min read
·
Tristan Manalac
Policy

Bayer’s Lymphoma Treatment Aliqopa to be Pulled from US Market

After a Phase III trial did not meet its primary endpoint, Bayer will voluntarily withdraw Aliqopa (copanlisib) from the U.S. market following discussions with the FDA.

November 15, 2023
·
2 min read
·
Tyler Patchen
Business

Alkermes Spins Off Oncology Business with $275M to Focus on Neuroscience

The new company, Mural Oncology, will continue registrational studies of its IL-2 cytokine in melanoma and ovarian cancer utilizing a $275 million cash runway expected to take them to the end of 2025.

November 15, 2023
·
2 min read
·
Kate Goodwin
Drug Development

The Next Generation of Weight Loss Drugs is Rapidly Approaching

Successful drugs from Novo Nordisk and Eli Lilly are just the beginning of what one analyst says could be “the largest therapeutic class of drugs that the biopharma industry has ever seen.”

November 15, 2023
·
5 min read
·
Amanda Heidt
Career Advice

Career Coach: Does LinkedIn’s ‘Open to Work’ Banner Make Me Look Desperate?

Carina Clingman, founder of The Collaboratory Career Hub, answers questions about the ins and outs of finding, landing and succeeding in biotech jobs.

November 15, 2023
·
7 min read
·
Carina Clingman
Drug Development

Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure

This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and human expertise.

November 15, 2023
·
1 min read
·
Lori Ellis
Business

Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash

Months after the FDA lifted its partial hold on their Phase II multiple myeloma program, Kite and Arcellx are expanding their existing development and commercialization collaboration in the blood cancer space.

November 15, 2023
·
2 min read
·
Tristan Manalac
Job Trends

New Initiatives Pump Money into Cell and Gene Therapy Development in New York

The Empire State is seeing large infusions of funds from the state and the Chan Zuckerberg Initiative to develop therapies for cancer and other applications.

November 15, 2023
·
5 min read
·
Charlotte LoBuono
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

Valneva SE announced the availability of documentation for its Extraordinary General Meeting which will be held on December 20, 2023 at 2:00 p.m. CET at the Radisson Blu Hotel, 6 place Aristide Briand, 44000 Nantes, France.

November 15, 2023
·
5 min read